Products for Research Use Only
RegisterLogin

PRN694

CAT: 0804-HY-12680-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12680-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PRN694 is an irreversible, highly selective and potent covalent interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) dual inhibitor with IC50s of 0.3 nM and 1.4 nM, respectively. PRN694 exhibits extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo[1].
CAS Number
1575818-46-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Itk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/PRN694.html
Purity
99.0
Solubility
DMSO : 125 mg/mL (ultrasonic; warming)
Smiles
O=C(C1=CC=C(C(F)F)S1)NC2=NC3=CC(CN[C@@H](C)C(C)(C)C)=CC=C3N2C[C@@H]4N(C(C=C)=O)CCC4
Molecular Formula
C28H35F2N5O2S
Molecular Weight
543.67
Precautions
H302, H315, H319, H335
References & Citations
[1]Zhong Y, et al. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. J Biol Chem. 2015 Mar 6;290 (10) :5960-78.|[2]Cho HS, et al. A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression. J Immunol. 2015 Nov 15;195 (10) :4822-31.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA8983-5PRN694
A16998-100PRN694 100mg
A16998-5PRN694 5mg
A16998-50PRN694 50mg
A16998-25PRN694 25mg
A16998-10PRN694 10mg
A16998-1PRN694 1mg

Popular Products